Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6P4F2
UPID:
FDX2_HUMAN
Alternative names:
Adrenodoxin-like protein; Ferredoxin-1-like protein
Alternative UPACC:
Q6P4F2; B7Z6L7; Q8N8B8
Background:
Ferredoxin-2, mitochondrial, known alternatively as Adrenodoxin-like protein or Ferredoxin-1-like protein, plays a pivotal role in the mitochondrial iron-sulfur protein biogenesis. It acts as an electron donor in the core iron-sulfur cluster (ISC) assembly complex, facilitating the reduction of persulfide into sulfide during [2Fe-2S] clusters assembly on ISCU. This process is crucial for the synthesis of [2Fe-2S] clusters, essential components in various biological processes.
Therapeutic significance:
Ferredoxin-2, mitochondrial, is linked to Mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy, a disorder characterized by recurrent episodes of weakness and myalgia. Understanding the role of Ferredoxin-2 could open doors to potential therapeutic strategies for this and related neuromuscular disorders.